7Baggers
 Published on: 2025-10-02 20:30:24  newser.com Fri, 03 Oct 2025 01:30:24 GMT
 Published on: 2025-10-01 08:38:29  newser.com Wed, 01 Oct 2025 13:38:29 GMT
 Published on: 2025-09-29 14:28:46  newser.com Mon, 29 Sep 2025 19:28:46 GMT
 Published on: 2025-09-29 11:38:34  newser.com Mon, 29 Sep 2025 16:38:34 GMT
 Published on: 2025-09-29 07:57:40  newser.com Mon, 29 Sep 2025 12:57:40 GMT
 q3 eps estimate for allogene therapeutics lifted by analyst  MarketBeat Thu, 11 Sep 2025 10:25:22 GMT
 q3 eps estimate for allogene therapeutics lifted by analyst  MarketBeat Wed, 10 Sep 2025 07:00:00 GMT
 zacks research issues positive forecast for allo earnings  MarketBeat Wed, 10 Sep 2025 02:12:40 GMT
 agio stock falls as fda delays decision on pyrukynd for thalassemia  The Globe and Mail Fri, 05 Sep 2025 15:10:00 GMT
 | marketbeat  MarketBeat Thu, 04 Sep 2025 07:00:00 GMT
 allogene therapeutics earnings call: progress amid challenges  TipRanks Mon, 01 Sep 2025 00:15:22 GMT
 allogene therapeutics earnings call: progress amid challenges  TipRanks Sun, 31 Aug 2025 07:00:00 GMT
 published on: 2025-08-30 17:42:49  Newser Sat, 30 Aug 2025 22:42:49 GMT
 tampa bay times sponsored content  Tampa Bay Times Sat, 30 Aug 2025 20:41:25 GMT
 published on: 2025-08-29 13:11:47  Newser Fri, 29 Aug 2025 18:11:47 GMT
 published on: 2025-08-27 07:39:07  Newser Wed, 27 Aug 2025 12:39:07 GMT

Allogene Therapeutics, Inc
(NASDAQ:ALLO) 

ALLO stock logo

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candi...

Founded: 2017
Full Time Employees: 264
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends